Naja, ist zwar vom 12.1.2016 aber hier wird davon gesprochen, das man einen weiteren Partner ausgemacht hat.
http://www.medpagetoday.com/reading-room/aga/lower-gi/61789
Bile Acid Modulator
Emerging pharmacologic agents that show promise in IBS-C were outlined in a monograph by Brian E. Lacy, MD, PhD, of Dartmouth Geisel School of Medicine in New Hampshire and colleagues in Gastroenterology & Hepatology.
One such agent is elobixibat, a minimally absorbed ileal bile acid transporter inhibitor. It reduces the reuptake of bile acids in the ileum, thereby resulting in a net increase of bile acids entering the colon, which in turn increases motility and transit. In studies of chronic idiopathic constipation (CIC) – a condition similar to IBS but lacking the pain component of IBS-C -- elobixibat improved the frequency of bowel movements, loosened stool consistency, and decreased straining.
While studies in IBS-C have yet to be conducted, a double-blind, placebo-controlled trial of 36 women with functional constipation found that elobixibat significantly accelerated overall colonic transit (P=0.059).
A phase II study of CIC patients used a primary endpoint of the change in the number of spontaneous bowel movements during week 1 versus baseline. The mean increase in spontaneous bowel movements was 1.7 for placebo versus 2.5, 4.0, and 5.4 for elobixibat at differing doses of 5 mg, 10 mg (P<0.002), and 15 mg (P<0.001), respectively.
Chey noted that a Phase III study of elobixibat was put on hold when problems of drug distribution arose. "One of the partners withdrew, but they have since identified another partner and it should be back in phase III trials," he said. "The phase II data looked really good, with a clear increase in frequency of bowel movements at the highest dose."
|
Thread abonnieren
